Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9230
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavis, Ian Den
dc.date.accessioned2015-05-15T22:14:35Z
dc.date.available2015-05-15T22:14:35Z
dc.date.issued2000-06-01en
dc.identifier.citationImmunology and Cell Biology; 78(3): 179-95en
dc.identifier.govdoc10849106en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9230en
dc.description.abstractThe survival of patients with cancer has improved steadily but incrementally over the last century, with the advent of effective anticancer treatments such as chemotherapy and radiotherapy. However, the majority of patients with metastatic disease will not be cured by these measures and will eventually die of their disease. New and more effective methods of treating these patients are required urgently. The immune system is a potent force for rejecting transplanted organs or microbial pathogens, but effective spontaneous immunologically induced cancer remissions are very rare. In recent years, much has been discovered about the mechanisms by which the immune system recognizes and responds to cancers. The specific antigens involved have now been defined in many cases. Improved adjuvants are available. Means by which cancer cells overcome immunological attack can be exploited and overcome. Most importantly, the immunological control mechanisms responsible for initiating and maintaining an effective immune response are now much better understood. It is now possible to manipulate immunological effector cells or antigen-presenting cells ex vivo in order to induce an effective antitumour response. At the same time, it is possible to recruit other aspects of the immune system, both specific (e.g. antibody responses) and innate (natural killer cells and granulocytes).en
dc.language.isoenen
dc.subject.otherAdjuvants, Immunologic.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonal.therapeutic useen
dc.subject.otherAntigens, Neoplasm.immunology.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherHumansen
dc.subject.otherImmunization, Passiveen
dc.subject.otherImmunotherapyen
dc.subject.otherImmunotherapy, Activeen
dc.subject.otherNeoplasms.therapyen
dc.subject.otherPeptides.immunology.therapeutic useen
dc.titleAn overview of cancer immunotherapy.en
dc.typeJournal Articleen
dc.identifier.journaltitleImmunology and cell biologyen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Repat Cancer Centre, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1046/j.1440-1711.2000.00906.xen
dc.description.pages179-95en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/10849106en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.